TWO SIGMA ADVISERS, LP - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$2,233,168
+2.1%
3,749,442
-1.4%
0.01%0.0%
Q2 2023$2,187,797
+22.3%
3,803,542
+49.5%
0.01%
+20.0%
Q1 2023$1,788,418
+48.3%
2,544,342
+376.8%
0.01%
+66.7%
Q4 2022$1,206,031
-40.5%
533,642
-15.8%
0.00%
-50.0%
Q3 2022$2,028,000
+224.5%
633,642
+285.1%
0.01%
+200.0%
Q2 2022$625,000
-29.1%
164,542
+0.6%
0.00%0.0%
Q1 2022$881,000
-69.5%
163,542
-23.6%
0.00%
-71.4%
Q4 2021$2,892,000
+286.6%
214,042
+414.0%
0.01%
+250.0%
Q3 2021$748,000
+133.8%
41,642
+123.4%
0.00%
+100.0%
Q2 2021$320,000
-31.5%
18,642
-20.1%
0.00%0.0%
Q1 2021$467,000
+33.8%
23,342
+13.6%
0.00%0.0%
Q4 2020$349,000
-53.7%
20,542
-54.8%
0.00%
-50.0%
Q3 2020$754,000
+179.3%
45,442
+290.3%
0.00%
+100.0%
Q2 2020$270,000
-49.2%
11,642
-52.8%
0.00%0.0%
Q4 2019$532,000
+4.5%
24,642
+59.3%
0.00%0.0%
Q4 2018$509,000
-96.8%
15,472
-94.1%
0.00%
-97.4%
Q3 2018$16,015,000
+5.7%
262,714
-15.3%
0.04%
-4.9%
Q2 2018$15,153,000
+338.8%
310,314
+436.7%
0.04%
+355.6%
Q4 2017$3,453,000
+111.1%
57,814
-15.2%
0.01%
+80.0%
Q3 2017$1,636,000
+73.1%
68,172
+41.0%
0.01%
+66.7%
Q2 2017$945,000
-78.8%
48,362
-74.5%
0.00%
-80.0%
Q1 2017$4,450,000
+11.6%
189,614
-41.7%
0.02%0.0%
Q4 2016$3,988,000
-3.0%
324,999
+35.8%
0.02%
-16.7%
Q3 2016$4,112,000
+1876.9%
239,367
+1840.6%
0.02%
+1700.0%
Q4 2015$208,000
-61.6%
12,335
-64.7%
0.00%
-75.0%
Q4 2014$542,00034,9770.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q4 2019
NameSharesValueWeighting ↓
Camber Capital Management LP 2,000,000$67,200,0003.35%
First Light Asset Management, LLC 763,403$25,650,0003.33%
BRIDGER MANAGEMENT, LLC 1,238,489$41,613,0003.29%
Rhenman & Partners Asset Management AB 734,445$24,677,0002.89%
BB BIOTECH AG 2,020,676$67,895,0001.71%
Gs Investments, Inc. 54,200$1,821,120,0001.43%
Artal Group S.A. 900,000$30,240,0001.24%
Cormorant Asset Management, LP 500,000$16,800,0001.14%
TOBAM 640,547$21,522,0001.09%
Bellevue Group AG 430,026$14,449,0000.80%
View complete list of NEKTAR THERAPEUTICS shareholders